CLL Society
WHAT’S NEW
Your connection to the most current news, information, and data about Chronic Lymphocytic Leukemia.
We suggest you BOOKMARK this page and visit it often. All content was current as of the date it was published.
In science and in medicine, information is constantly changing. Published content may become out-of-date as new information and data emerge.
COVID-19 Updates
The FDA Authorizes Pharmacists to Prescribe Paxlovid to Eligible Patients Who Test Positive for COVID-19
This is part of a concerted effort to make sure all those with a high risk for progression to a severe case of COVID-19 have quick and easy access to appropriate therapy. In addition, since Paxlovid therapy should be started within five days of the infection, this change should help speed up the process.
Spontaneous Remission of Chronic Lymphocytic Leukemia in a Patient with SARS-CoV-2
This should not be part of anyone’s game plan. Still, it was nice to read that for at least this one 67-year-old asymptomatic CLL patient, a case of COVID-19 associated with low blood counts and a broad spectrum of treatments resulted in his CLL becoming undetectable in his bone marrow and blood, and his scans had all returned to normal.
FDA Authorizes Revisions to Evusheld Dosing
On June 29, 2022, the FDA announced its long-awaited guidelines on the timing of a second Evusheld dose.
Living with CLL
Harness the Mind
The purpose of this article is to share how to maintain a positive attitude through a cancer journey. Understand, this is one patient’s perspective. Having been an athlete my whole life, I realize the power of the mind. While I’m not able to change what’s happening to me inside my body, how I think about it has an impact.
The CLL Nurse’s Note: Understanding the Importance of Screening for Skin Cancer While Living with CLL/SLL
Recently, several questions have come into CLL Society from patients who were not aware that CLL/SLL also carries a higher risk of developing secondary cancers, particularly skin cancer.
My Journey: COVID-19, Evusheld, Paxlovid, and CLL
My Journey: COVID-19, EVUSHELD, PAXLOVID and CLL
SPECIAL FEATURE: World CLL Day is One Month Away
World CLL Day is coming up on September 1, 2022. This year’s campaign will continue to raise awareness about how those with CLL are still vulnerable to COVID-19, especially as restrictions have been lifted around the world.
Please join us on September 1st to help raise awareness of CLL/SLL by sharing your story. Visit the campaign website for more details and stay tuned for ways you can get involved.
How to Get Involved
UPCOMING EVENTS
It’s Not Over Yet: The Ongoing Impact of COVID-19 for those with CLL/SLL
Wednesday, August 24th at 11 AM PT / 2 PM ET
As much of the world has seemingly moved on from COVID-19, the virus continues to pose serious risks for those who are immunocompromised. However, as more options for protection and treatment are being developed, we remain hopeful for the future! Infectious disease specialist, Dr. Shmuel Shoham, will briefly present some of the newest clinical updates and guidance, with the remainder of the event being dedicated to answering audience questions.
On-Demand Replay
If you missed the August 2nd CLL Society webinar, CAR-T and Other Cellular Therapies in CLL: The Present and Future, you can watch the replay here.
If you missed the June 28th CLL Society webinar, The Evolving Role of BTKi’s in CLL, you can watch the replay here.
Treatment Updates
ASH 2021: Dr. Megan Thompson on Outcomes of Subsequent Therapies after Exposure to Bruton’s Tyrosine Kinase Inhibitors and Venetoclax
We discuss results from two new studies, which looked at real-world outcomes of subsequent therapies in patients whose disease progressed after either 1) double-exposure to a covalent BTK inhibitor and venetoclax or 2) exposure to a non-covalent BTK inhibitor.
ASH 2021: Dr. Jeff Sharman on Zanubrutinib for BTK Inhibitor-Intolerant Patients with Chronic Lymphocytic Leukemia (CLL)
At the American Society of Hematology (ASH) 2021, our own Dr. Brian Koffman interviewed Dr. Jeff Sharman, a hematologist/oncologist at Willamette Valley Cancer Institute in Eugene, OR. They discussed zanubrutinib and its use in patients who could not tolerate previous BTK inhibitors.
ASH 2021: Real-World Evaluation of the Treatment Landscape for Chronic Lymphocytic Leukemia
mothy Smith and colleagues presented this research at the American Society for Hematology annual meeting held in December 2021 (ASH 2021).
Equitable Access and Regulatory News
ASH 2021: Dr. Deborah Stephens on Racial Disparities in Telemedicine Uptake During the COVID-19 Pandemic Among Patients with Blood Cancers
We discuss results from a study looking at racial disparities in the use of telemedicine during the COVID-19 pandemic.
